



**PRESS RELEASE** Contact: Michael Senken  
Phone: (678) 384-6720

## **MiMedx Group, Inc. to Present at the 13<sup>th</sup> Annual Needham Growth Conference**

**MARIETTA, Georgia, Friday, January 7, 2011** (PR Newswire) – MiMedx Group, Inc. (MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it will present at the 13<sup>th</sup> Annual Needham Growth Conference in New York. Parker H. “Pete” Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, CFO of MiMedx, are scheduled to present on Thursday, January 13th, at 9:40 a.m. Eastern Time at the New York Palace Hotel in New York City. A webcast of this presentation will be available on the Company’s website, [www.mimedx.com](http://www.mimedx.com).

### **About the Company**

MiMedx is an integrated developer, manufacturer and marketer of patent protected biomaterial-based products and bioimplants processed from human amniotic membrane. The Company is successfully emerging from a development-focused start-up into a fully integrated operating company with an experienced team poised to capitalize on its science and technology to generate sales growth and profitability. Our mantra is "Repair, don't replace" because our biochemists, engineers, designers and physicians believe it is better to augment repair when possible rather than replace traumatized, but otherwise healthy tissues and structures. Our platform technologies, HydroFix™ and CollaFix™, and our newest platform processing technology, Purion® developed by our wholly-owned subsidiary, Surgical Biologics, have a vast number of potential applications in treating traumatized tissue and structures. MiMedx is focused on commercializing multiple applications for the Company’s three technology platforms. In parallel, we are seeking strategic relationships, in selective categories, to more rapidly commercialize our technologies.